Loss of Appetite: Labs, Causes, and Next Steps

Updated Jan 28, 2025

Image: HealthRX.com clinical image

Loss of appetite, medically called anorexia, means a reduced or absent drive to eat that persists beyond a single missed meal. This is distinct from anorexia nervosa, a psychiatric eating disorder defined by intentional caloric restriction and disturbed body image. The two are frequently confused, and treating an older adult's medication-related appetite loss as if it were an eating disorder (or vice versa) delays the correct workup.

At a glance

Definition / reduced desire to eat lasting more than a few days, with or without weight loss
First-line labs to discuss with a clinician / CBC, comprehensive metabolic panel, TSH, inflammatory markers, glucose/HbA1c, urinalysis, and HIV screening in patients with risk factors
Red flags / unintentional weight loss, dysphagia, persistent vomiting, night sweats, a palpable mass, or new neurologic symptoms
Most common reversible causes / medication effects, acute illness, and depression
GLP-1 connection / semaglutide and tirzepatide suppress appetite as part of their intended mechanism
Typical escalation window / red-flag cases are usually evaluated within one to two weeks rather than watched

Loss of appetite, or anorexia, is a symptom rather than a diagnosis, and its most common reversible causes in adults are medication effects, depression, and acute gastrointestinal illness. GLP-1 receptor agonists such as semaglutide and tirzepatide suppress appetite as an intended part of their mechanism, which is different from unexplained appetite loss arising from a new medical problem. Red-flag features, including unintentional weight loss, difficulty swallowing, a palpable mass, night sweats, or blood in the stool, warrant evaluation within one to two weeks rather than watchful waiting, because they raise the likelihood of malignancy, endocrine disease, or another condition that benefits from prompt diagnosis.

Why appetite loss deserves a real workup, not just reassurance

Appetite is regulated by a circuit that includes the hypothalamus, the vagus nerve, and circulating signals such as ghrelin (which promotes hunger) and leptin and peptide YY (which promote satiety). Inflammation, malignancy, certain drugs, and neurologic or endocrine disease can all disrupt this circuit. Because so many different systems feed into appetite, the symptom itself does not point to a cause. That is why a structured history, medication review, and a targeted panel of first-line labs matter more than any single "appetite test."

Common causes, organized by category

Medications: the most overlooked cause

Drug-induced appetite suppression is common and usually reversible once the offending medication is identified. Classes most often implicated include:

Opioids, through delayed gastric emptying and nausea
SSRIs and SNRIs, particularly in the first several weeks of treatment
Metformin, through gastrointestinal intolerance in a meaningful proportion of people starting it
Digoxin, even at doses within the usual therapeutic range
Topiramate and other anticonvulsants
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide), which suppress appetite intentionally as their core mechanism of action

A full medication reconciliation, including over-the-counter drugs and supplements, is a reasonable first step before ordering imaging.

Psychiatric and psychological causes

Depression is one of the more frequent drivers of appetite change seen in primary care. Appetite disturbance (either loss or increase) is one of the recognized symptom criteria for a major depressive episode. Anxiety disorders and acute grief also reduce appetite, plausibly through elevated cortisol and stress-hormone signaling that dampens hunger drive, though the exact mechanism in any individual patient is not something a lab test can confirm.

Gastrointestinal conditions

Structural GI disease can present with appetite loss before other symptoms appear:

Gastroparesis (delayed gastric emptying) causes early satiety and nausea and is more common in longstanding diabetes.
Peptic ulcer disease and H. pylori infection can suppress appetite through gastric inflammation.
Inflammatory bowel disease often produces appetite loss alongside other markers of active inflammation.
Hepatitis and cirrhosis reduce appetite through impaired liver function and systemic inflammation.
Colorectal and gastric cancer can present with appetite loss months before other symptoms, which is why unexplained, persistent cases in adults over 50 deserve attention.

Systemic and endocrine causes

Hypothyroidism slows gut motility and metabolic demand, causing early satiety; an elevated TSH is the standard screening abnormality.
Adrenal insufficiency (Addison's disease) classically combines nausea, fatigue, and salt craving with a low morning cortisol.
Chronic kidney disease, especially at more advanced stages, suppresses appetite through accumulated uremic toxins.
HIV infection can cause appetite loss and wasting even with modern antiretroviral therapy; testing follows current CDC guidance (CDC HIV testing).

Malignancy

Cancer-associated anorexia-cachexia syndrome is a distinct clinical entity, thought to be driven by tumor-related inflammatory signaling that suppresses hunger pathways in the hypothalamus. It becomes more common as cancer advances and is associated with worse outcomes. Unintentional weight loss of roughly 5% of body weight or more within six months, especially in someone over 50 with no obvious explanation, is the signal that typically prompts cancer screening rather than watchful waiting.

The lab workup: what a first evaluation usually includes

No single test diagnoses appetite loss. The goal of initial testing is to identify treatable causes and flag findings that change the urgency of workup.

A reasonable first-line panel to discuss with a clinician

Test	What it screens for
CBC with differential	Anemia, infection, lymphoma
Comprehensive metabolic panel	Kidney and liver function, electrolytes
TSH	Hypothyroidism and hyperthyroidism
CRP or ESR	Systemic inflammation or occult infection
Fasting glucose or HbA1c	Undiagnosed diabetes
LDH and uric acid	Consideration of lymphoma or another hematologic process
HIV antigen/antibody	HIV infection, per current CDC testing guidance
Urinalysis	Urinary tract infection, renal disease, glucosuria

Exact reference thresholds (for example, the specific TSH or CRP cutoff a lab uses) vary by laboratory and should come from the reporting lab, not from a generic list.

Second-tier testing based on history

Morning cortisol (and ACTH stimulation testing) when adrenal insufficiency is suspected
Celiac serology (anti-tTG IgA with total IgA) when iron-deficiency anemia or chronic GI symptoms are present
H. pylori stool antigen or urea breath test for dyspepsia
Age- and sex-appropriate tumor markers only when malignancy is a real clinical concern; these are not general screening tools
Upper endoscopy for new dyspepsia over age 60, or dysphagia, bleeding, or a strong family history of gastric cancer at any age

Imaging

CT of the abdomen and pelvis with contrast is often the most informative single study when malignancy or structural GI disease is on the differential. The American College of Radiology's Appropriateness Criteria address imaging choices for unexplained weight loss, which frequently accompanies appetite loss (ACR Appropriateness Criteria). Chest imaging and right-upper-quadrant ultrasound are added selectively based on the history and metabolic panel results.

Red flags that should shorten the timeline

Most appetite loss is benign and self-limited. The following features are widely used in clinical practice to justify evaluation within one to two weeks rather than a longer watch period:

Unintentional weight loss greater than roughly 5% of body weight within six months
New appetite loss after age 50 with no obvious explanation
Dysphagia or painful swallowing
Persistent vomiting or vomiting blood
A palpable abdominal or supraclavicular mass
Night sweats and drenching fevers
Blood in the stool or unexplained iron-deficiency anemia
New confusion, focal weakness, or other neurologic changes

A decision framework for deciding how fast to act

The hardest part of appetite loss is not memorizing causes, it is deciding how urgently to act on a symptom that is usually benign but occasionally is not. The framework below organizes that decision by two variables that actually change management: whether a red flag is present, and how long the appetite loss has lasted.

Situation	What it suggests	Reasonable next step
Any red flag from the list above, regardless of duration	Higher concern for malignancy, structural GI disease, or a systemic process needing prompt treatment	In-person evaluation within days, with first-line labs and imaging ordered promptly rather than deferred
No red flag, but appetite loss has lasted more than about 4 weeks, or is accompanied by low mood, poor sleep, or loss of interest in usual activities	Possible depression, undiagnosed endocrine disease, or an evolving GI condition	Clinician visit with first-line lab panel; consider a validated depression screening tool if mood symptoms are present
No red flag, duration under 4 weeks, and a clear trigger (acute viral illness, new medication, recent stressful event)	Likely self-limited or medication-related	Reasonable to monitor with a defined follow-up point (for example, 2 weeks), address hydration and nutrition, and reassess if it does not improve or a red flag develops
New appetite suppression after starting or increasing the dose of a GLP-1 receptor agonist	Expected pharmacologic effect in most cases, but can be excessive in some patients	Discuss with the prescriber; slowing the dose-escalation schedule is the usual first step rather than adding an appetite stimulant

This is a general decision aid, not a substitute for a clinician's judgment about an individual patient, and it does not replace urgent or emergency evaluation when red-flag symptoms are severe (for example, an inability to keep down fluids, or signs of significant dehydration).

Treatment: address the cause first

Treating the underlying cause

Correcting hypothyroidism with levothyroxine, switching an appetite-suppressing medication, or treating H. pylori with standard combination antibiotic and acid-suppressing therapy each address a root cause directly rather than masking the symptom. Dosing of any of these treatments needs to be individualized by the prescribing clinician; this article does not provide dosing guidance.

Pharmacologic appetite stimulants

Three medications have the most established evidence, though their approved uses are narrower than their off-label use:

Megestrol acetate is FDA-approved for AIDS-related anorexia and is used off-label in cancer-associated anorexia-cachexia. Clinical trials have reported appetite improvement with megestrol without a clear survival benefit, and thromboembolic risk is a recognized concern; the specific trial data supporting this should be verified against the primary literature before being cited with exact figures.
Dronabinol, a synthetic cannabinoid, is FDA-approved for AIDS-related anorexia. Evidence for benefit in cancer-related appetite loss is more modest and inconsistent than for megestrol.
Mirtazapine is an antidepressant with appetite-stimulating and mild sedating properties, used off-label for appetite loss, particularly when depression is also present. It is a reasonable option to discuss with a prescriber when mood and appetite symptoms overlap, though it is not FDA-approved specifically for appetite stimulation.

Nutritional support

Oral nutritional supplements and small, calorie-dense meals eaten more frequently are commonly recommended, non-pharmacologic first steps, especially in malnourished or hospitalized patients. A registered dietitian can individualize recommendations, including strategies for taste changes common during chemotherapy.

Exercise

Resistance exercise has been studied as a way to support appetite and lean mass in older adults with reduced appetite, though the size of this effect and the durability of any benefit needs confirmation from current trial data before being stated as a precise number. Testosterone replacement in men with cancer-associated cachexia and confirmed low testosterone may support lean mass, but its effect on appetite specifically remains preliminary.

GLP-1 medications and intentional appetite suppression

GLP-1 receptor agonists suppress appetite as a core, intended part of how they produce weight loss, not as an incidental side effect. According to FDA prescribing information, decreased appetite is listed among the common adverse events for these medications, alongside nausea and vomiting, and these effects are typically most prominent during dose escalation (verify current label language and percentages at accessdata.fda.gov, since labeling can change and this should be dated at the time it is cited).

For someone being evaluated for unexplained appetite loss, a GLP-1 agonist prescribed for weight management or diabetes is not itself the diagnosis to chase, it is a known and expected mechanism that should be part of the medication review. When appetite suppression on a GLP-1 agonist is more pronounced than expected or is causing nutritional concerns, the usual first step discussed with prescribers is to slow the dose-escalation schedule rather than add a separate appetite stimulant.

Special populations

Older adults

Age-related appetite decline, sometimes called "anorexia of aging," results from a combination of reduced smell and taste sensitivity, slower gastric emptying, and social factors such as isolation. It should be treated as a diagnosis of exclusion: reversible causes need to be ruled out first, because unintentional weight loss in older adults is associated with meaningfully worse outcomes and should not be dismissed as expected aging.

Pregnancy

Nausea and reduced appetite are common in early pregnancy. Persistent vomiting with significant weight loss can indicate hyperemesis gravidarum, which requires medical evaluation, hydration, and sometimes prescription antiemetic therapy. This is a distinct condition from ordinary morning sickness and needs obstetric management rather than self-treatment.

Children

New food refusal in a toddler is often normal developmental pickiness. Persistent appetite loss in a school-age child, especially with fatigue or pallor, is a reasonable indication for a CBC to evaluate for iron-deficiency anemia, which remains a common and treatable finding in young children.

What is established, what is plausible, and what is not established

Established: Medication effects, depression, acute illness, and GI conditions are common and often reversible causes of appetite loss. GLP-1 receptor agonists suppress appetite as an intended mechanism, per FDA labeling. Red-flag features (unintentional weight loss, dysphagia, a palpable mass, GI bleeding, night sweats, neurologic change) warrant faster evaluation than appetite loss without those features. Megestrol and dronabinol carry FDA approval specifically for AIDS-related anorexia, not for appetite loss generally.

Plausible but not firmly quantified on this page: The exact prevalence of appetite loss in older adults or in cancer populations, the precise magnitude of benefit from resistance exercise or oral nutritional supplements, and exact adverse-event percentages for specific GLP-1 products. These figures exist in the primary literature and FDA labeling, but the numbers previously cited on this page could not be verified against a specific, correctly matched source and have been described qualitatively instead.

Not established from the material available here: Any claim that a specific supplement, over-the-counter product, or single lab value can reliably diagnose the cause of appetite loss without clinical evaluation.

When to seek urgent or emergency care

Seek prompt in-person evaluation, not just a message to a clinician, if appetite loss is accompanied by an inability to keep down fluids, signs of dehydration, confusion, chest pain, difficulty breathing, or vomiting blood. These situations should not wait for a scheduled visit.

Frequently asked questions

What causes loss of appetite?

The most common reversible causes are medication side effects (opioids, SSRIs, metformin, and GLP-1 agonists among them), depression, gastrointestinal infections, and acute viral illness. Less common but more serious causes include thyroid disease, adrenal insufficiency, chronic kidney disease, hepatitis, and malignancy. A medication review and a targeted lab panel identify the cause in most cases.

How is loss of appetite diagnosed?

Diagnosis starts with a history, physical exam, and medication review, followed by first-line labs such as a CBC, comprehensive metabolic panel, TSH, inflammatory markers, glucose or HbA1c, and HIV screening where indicated. Second-tier tests like morning cortisol, celiac serology, or tumor markers are added based on clinical suspicion, not ordered routinely.

When should I worry about loss of appetite?

Evaluation within one to two weeks is reasonable if there is unintentional weight loss of roughly 5% of body weight or more in six months, difficulty swallowing, blood in the stool, a palpable mass, night sweats, or new neurologic symptoms. Appetite loss lasting more than about four weeks without an obvious cause also warrants a clinician visit.

Can stress and anxiety cause loss of appetite?

Yes. Psychological stress and anxiety are recognized, common causes of reduced appetite, and they typically improve once the underlying stressor or mood disorder is addressed, sometimes with therapy or medication.

Is loss of appetite a side effect of GLP-1 medications?

Yes. Appetite suppression is part of the intended mechanism of GLP-1 receptor agonists such as semaglutide and tirzepatide, and decreased appetite is listed as a common adverse event in FDA prescribing information. If suppression becomes excessive, the usual first step is to slow the dose-escalation schedule with the prescriber rather than add a separate appetite stimulant.

What medications can help stimulate appetite?

Megestrol acetate and dronabinol both carry FDA approval specifically for AIDS-related anorexia and are sometimes used off-label for other causes of appetite loss, including cancer-related cachexia. Mirtazapine, an antidepressant, is used off-label and is often preferred when depression and appetite loss occur together. Each carries its own risks and should be prescribed based on the underlying cause, not used as a first response to appetite loss of unknown cause.

Does cancer always cause loss of appetite?

No. Early-stage cancers often cause no symptoms. Cancer-associated anorexia-cachexia syndrome becomes more common as cancer advances. Unintentional weight loss of around 5% or more of body weight within six months in someone over 50 is the clinical signal that typically prompts cancer screening, not appetite loss alone.

Sources for general claims referenced above: CDC HIV testing guidance; American College of Radiology Appropriateness Criteria; FDA drug label database. Specific trial results, exact prevalence figures, and precise adverse-event percentages mentioned qualitatively in this draft should be verified against the current primary literature and current FDA labeling before publication, since a matching primary source could not be confirmed for several of the original page's numeric citations.